OpenAI buys biotech startup Orchestra Bio
The Indian American-led company, run by Ashoka Rajendra, will join OpenAI to advance its drug development programs at a larger scale.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
OpenAI has acquired Orchestra Bio, an Indian American-led company led by Ashoka Rajendra. The deal is aimed at expanding AI agents used in drug development. Coverage of the acquisition appeared on October 22 and 23.
Why it matters
The deal creates new opportunities and challenges for life sciences technology partners, according to coverage. It also signals the direction of OpenAI's strategy.
Coverage
- OpenAI acquires Ashoka Rajendra’s Orchestra Bio (americanbazaaronline.com)
- OpenAI Buys Orchestra Bio: 5 Things It Changes [2026] (tech-insider.org)
- OpenAI Acquires Orchestra Bio to Expand AI Agents for Drug Development (channelinsider.com)
- OpenAI acquired biotech startup Orchestra Bio to expand its life sciences AI tools (qz.com)
More from Technology & AI
- China puts humanoid robots to work serving food and sorting parcels
- Newsom proposes sweeping AI safety rules for Washington
- Google releases Gemini 4 Neon AI model with million-token context
- Microsoft and Intel widen their cloud chip partnership
- Google DeepMind rolls out Genie 4 to select subscribers
- AI helped AMD shorten chip design work, OpenAI says